Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsInvestigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospitalEvolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKRIntegrating Antimicrobial Therapy with Host Immunity to Fight Drug-Resistant Infections: Classical vs. Adaptive TreatmentVancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineagesDNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.Metronidazole resistance in Prevotella spp. and description of a new nim gene in Prevotella baroniae.Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanismsExposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureusUnderestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysisSccmec type II gene is common among clinical isolates of methicillin-resistant Staphylococcus aureus in Jakarta, IndonesiaIsolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure.In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptidesStaphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.Rapid induction of high-level carbapenem resistance in heteroresistant KPC-producing Klebsiella pneumoniae.Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Current diagnosis and treatment of infective endocarditis.Stepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene.Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA).Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.The pharmacokinetic and pharmacodynamic properties of vancomycin.Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.Staphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings.Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.Modulation of fibronectin adhesins and other virulence factors in a teicoplanin-resistant derivative of methicillin-resistant Staphylococcus aureus.The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections.Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).Minimum inhibitory concentration of vancomycin to methicillin resistant Staphylococcus aureus isolated from different clinical samples at a tertiary care hospital in Nepal.Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistanceSynergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus.LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus.Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin.Heteroresistance at the single-cell level: adapting to antibiotic stress through a population-based strategy and growth-controlled interphenotypic coordination.
P2860
Q24646677-E33EF3E3-DD21-4A2B-8D72-BB6D0533ED57Q24810927-56474B0D-451E-41C3-A691-F9DF32C3AEDEQ28477900-7C13860A-0F1F-4087-A2CF-C233AE0289D0Q28551361-EFFA7EDF-8A52-4D7B-8D9A-A747DC3A5689Q30341876-12385B93-2508-4C28-9156-5A069C1A84CBQ33220466-8F620DB9-8C59-4DFF-A082-4DED3394F81AQ33558893-245BED45-0235-4275-A42B-E1D837BC0E4BQ34045273-416D0BDA-5584-474B-98E9-C1B0A8B8989DQ34045376-B600A1B6-C835-4261-892C-0F034017EB32Q34057324-8165513F-60D2-4F45-A1DB-0B4FE78F30FAQ34108614-FFDBA9A5-0F64-4079-9361-AEE91304EFC8Q34141289-0F079983-1632-4417-AA8D-C933F6A2B4CCQ34157657-72DFFD49-60BC-4C13-94C9-24887D281A74Q34405301-9077A65B-3076-415C-AF56-F46E17ACC25AQ34632750-7BFBAA73-311E-405A-A346-464FFF018EC5Q35023343-CD223C88-4915-4767-81E4-D357A193601DQ35038242-7EF982A3-C964-4A65-A527-090B0B5F8475Q35083990-2914BCF2-4088-4C56-B009-0347F43872EDQ35541702-3E6259B5-F013-4FE2-BF7A-BAA9C23BA5D3Q35598902-2CF768D6-004E-4254-8BAC-B5E6D2A56987Q35607909-33EAE6F1-C026-4B39-B074-525460E352FCQ35806369-CEFE5764-CB96-4205-BBC9-0266A2AFD451Q35917305-621F80EA-F21B-44E2-A689-51EBE9F9C707Q36158472-1F354C8D-33CA-41E1-95FE-0DDD65C22ECDQ36315377-4A98845A-E4D1-4AE0-87CD-29C74A878307Q36328966-03E269DD-9D46-47BA-88F3-3E0E4C83EB9AQ36328971-C8EED52A-F7C3-4028-ADE1-CBF1F839B1DBQ36422686-3A71F0AC-334E-42BC-B9D2-55483203F445Q36478309-13917CDB-5EE4-40AE-8D2B-277B9B1F7E36Q36667211-FEE8CBDF-29BC-4F7D-B721-CE50C6AD8212Q36670735-7AA0090A-3218-4F92-AA79-86CBECF536C7Q36779557-0FAAAC2E-5F39-4446-B240-7E39870E8974Q36847287-7BEF4085-C137-40AC-A9EC-F1C0F16FF5D2Q36898180-FD4A6BBB-8626-42B3-A922-BAB30C5E95EBQ37113323-5CF29C51-BFAD-4994-A972-4CCF9777B224Q37263514-010D4E5E-3143-492C-9DC1-5CE2FF384307Q37323867-4DE9BA84-671D-4972-AD61-BB330E4ED85BQ37598693-98A70DCB-CF72-461B-8D24-983A01812497Q37625238-9AA4F6BB-A3D7-4CBE-B247-5832250B3DDFQ37631528-6774A592-C33D-4E0A-954F-178D779791D1
P2860
Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Vancomycin treatment failure a ...... rabbit model of endocarditis.
@ast
Vancomycin treatment failure a ...... rabbit model of endocarditis.
@en
Vancomycin treatment failure a ...... rabbit model of endocarditis.
@nl
type
label
Vancomycin treatment failure a ...... rabbit model of endocarditis.
@ast
Vancomycin treatment failure a ...... rabbit model of endocarditis.
@en
Vancomycin treatment failure a ...... rabbit model of endocarditis.
@nl
prefLabel
Vancomycin treatment failure a ...... rabbit model of endocarditis.
@ast
Vancomycin treatment failure a ...... rabbit model of endocarditis.
@en
Vancomycin treatment failure a ...... rabbit model of endocarditis.
@nl
P2093
P2860
P1476
Vancomycin treatment failure a ...... rabbit model of endocarditis.
@en
P2093
Françoise Perdreau-Remington
Henry F Chambers
Matthew R Moore
P2860
P304
P356
10.1128/AAC.47.4.1262-1266.2003
P407
P577
2003-04-01T00:00:00Z